Here, we determined the activity dynamics of orexin neurons during sleep that suppress the abnormal REM sleep architecture of narcolepsy.

The post Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy appeared first on SRI.

We describe here a model of opioid withdrawal in mice that resembles the sleep phenotype characteristic of withdrawal in humans.

The post Biological sex influences sleep phenotype in mice experiencing spontaneous opioid withdrawal appeared first on SRI.

Over 40 years have elapsed since the original description of the effects of sodium gamma-hydroxybutyrate (GHB) on sleep [1] and the subsequent description of GHB as an effective treatment for narcolepsy [2, 3], yet the neurobiological basis for its efficacy in narcolepsy remains a mystery.

The post The mystery of gamma-hydoxybutyrate efficacy in narcolepsy type 1 appeared first on SRI.

In the present study, we systematically evaluated the efficacy of two NOPR agonists, Ro64-6198 and SR16835, on sleep/wake in rats, mice, and Cynomolgus macaques.

The post Activation of the nociceptin/orphanin-FQ receptor promotes NREM sleep and EEG slow wave activity appeared first on SRI.

We evaluated the efficacy of two small molecule hypocretin/orexin receptor-2 (HCRTR2) agonists in narcoleptic male orexin/tTA; TetO-DTA mice.

The post Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK-925 and ARN-776 in narcoleptic <em>orexin/tTA; TetO-DTA</em> mice appeared first on SRI.

We compared the development of narcoleptic symptomatology in male vs. female orexin-tTA; TetO-DTA mice, a model in which Hcrt neuron degeneration can be initiated by removal of doxycycline (DOX) from the diet.

The post The development of sleep/wake disruption and cataplexy as hypocretin/orexin neurons degenerate in male vs. female Orexin/tTA; TetO-DTA Mice  appeared first on SRI.

Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear.

The post Cerebrospinal Fluid Monoamine Levels in Central Disorders of Hypersomnolence appeared first on SRI.